future glp-1 drugs Changed Obesity Treatment. The Next Challenge May Be Clinical Trial Capacity GLP-1 Drugs: Fighting Diabetes and

We also assess the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with GLP1R agonists and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development

First Things First, What Is A Black Box Warning

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

So its this vicious cycle

These novel treatments aim to not only help patients shed excess weight but also improve metabolic health, reducing the risk of obesity-related conditions like diabetes and cardiovascular disease

A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of certain cancers through improved insulin regulation and immune modulation